J Lloyd Holder1, Michael M Quach2. 1. Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, U.S.A.. holder@bcm.edu. 2. Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, U.S.A.
Abstract
OBJECTIVE: The coincidence of autism with epilepsy is 27% in those individuals with intellectual disability.1 Individuals with loss-of-function mutations in SHANK3 have intellectual disability, autism, and variably, epilepsy.2-5 The spectrum of seizure semiologies and electroencephalography (EEG) abnormalities has never been investigated in detail. With the recent report that SHANK3 mutations are present in approximately 2% of individuals with moderate to severe intellectual disabilities and 1% of individuals with autism, determining the spectrum of seizure semiologies and electrographic abnormalities will be critical for medical practitioners to appropriately counsel the families of patients with SHANK3 mutations. METHODS: A retrospective chart review was performed of all individuals treated at the Blue Bird Circle Clinic for Child Neurology who have been identified as having either a chromosome 22q13 microdeletion encompassing SHANK3 or a loss-of-function mutation in SHANK3 identified through whole-exome sequencing. For each subject, the presence or absence of seizures, seizure semiology, frequency, age of onset, and efficacy of therapy were determined. Electroencephalography studies were reviewed by a board certified neurophysiologist. Neuroimaging was reviewed by both a board certified pediatric neuroradiologist and child neurologist. RESULTS: There is a wide spectrum of seizure semiologies, frequencies, and severity in individuals with SHANK3 mutations. There are no specific EEG abnormalities found in our cohort, and EEG abnormalities were present in individuals diagnosed with epilepsy and those without history of a clinical seizure. SIGNIFICANCE: All individuals with a mutation in SHANK3 should be evaluated for epilepsy due to the high prevalence of seizures in this population. The most common semiology is atypical absence seizure, which can be challenging to identify due to comorbid intellectual disability in individuals with SHANK3 mutations; however, no consistent seizure semiology, neuroimaging findings, or EEG findings were present in the majority of individuals with SHANK3 mutations. Wiley Periodicals, Inc.
OBJECTIVE: The coincidence of autism with epilepsy is 27% in those individuals with intellectual disability.1 Individuals with loss-of-function mutations in SHANK3 have intellectual disability, autism, and variably, epilepsy.2-5 The spectrum of seizure semiologies and electroencephalography (EEG) abnormalities has never been investigated in detail. With the recent report that SHANK3 mutations are present in approximately 2% of individuals with moderate to severe intellectual disabilities and 1% of individuals with autism, determining the spectrum of seizure semiologies and electrographic abnormalities will be critical for medical practitioners to appropriately counsel the families of patients with SHANK3 mutations. METHODS: A retrospective chart review was performed of all individuals treated at the Blue Bird Circle Clinic for Child Neurology who have been identified as having either a chromosome 22q13 microdeletion encompassing SHANK3 or a loss-of-function mutation in SHANK3 identified through whole-exome sequencing. For each subject, the presence or absence of seizures, seizure semiology, frequency, age of onset, and efficacy of therapy were determined. Electroencephalography studies were reviewed by a board certified neurophysiologist. Neuroimaging was reviewed by both a board certified pediatric neuroradiologist and child neurologist. RESULTS: There is a wide spectrum of seizure semiologies, frequencies, and severity in individuals with SHANK3 mutations. There are no specific EEG abnormalities found in our cohort, and EEG abnormalities were present in individuals diagnosed with epilepsy and those without history of a clinical seizure. SIGNIFICANCE: All individuals with a mutation in SHANK3 should be evaluated for epilepsy due to the high prevalence of seizures in this population. The most common semiology is atypical absence seizure, which can be challenging to identify due to comorbid intellectual disability in individuals with SHANK3 mutations; however, no consistent seizure semiology, neuroimaging findings, or EEG findings were present in the majority of individuals with SHANK3 mutations. Wiley Periodicals, Inc.
Authors: J J Luciani; P de Mas; D Depetris; C Mignon-Ravix; A Bottani; M Prieur; P Jonveaux; A Philippe; G Bourrouillou; B de Martinville; B Delobel; L Vallee; M-F Croquette; M-G Mattei Journal: J Med Genet Date: 2003-09 Impact factor: 6.318
Authors: S U Dhar; D del Gaudio; J R German; S U Peters; Z Ou; P I Bader; J S Berg; M Blazo; C W Brown; B H Graham; T A Grebe; S Lalani; M Irons; S Sparagana; M Williams; J A Phillips; A L Beaudet; P Stankiewicz; A Patel; S W Cheung; T Sahoo Journal: Am J Med Genet A Date: 2010-03 Impact factor: 2.802
Authors: M C Phelan; R C Rogers; R A Saul; G A Stapleton; K Sweet; H McDermid; S R Shaw; J Claytor; J Willis; D P Kelly Journal: Am J Med Genet Date: 2001-06-15
Authors: Sara M Sarasua; Luigi Boccuto; Julia L Sharp; Alka Dwivedi; Chin-Fu Chen; Jonathan D Rollins; R Curtis Rogers; Katy Phelan; Barbara R DuPont Journal: Hum Genet Date: 2014-01-31 Impact factor: 4.132
Authors: Caroline Nava; Carine Dalle; Agnès Rastetter; Pasquale Striano; Carolien G F de Kovel; Rima Nabbout; Claude Cancès; Dorothée Ville; Eva H Brilstra; Giuseppe Gobbi; Emmanuel Raffo; Delphine Bouteiller; Yannick Marie; Oriane Trouillard; Angela Robbiano; Boris Keren; Dahbia Agher; Emmanuel Roze; Suzanne Lesage; Aude Nicolas; Alexis Brice; Michel Baulac; Cornelia Vogt; Nady El Hajj; Eberhard Schneider; Arvid Suls; Sarah Weckhuysen; Padhraig Gormley; Anna-Elina Lehesjoki; Peter De Jonghe; Ingo Helbig; Stéphanie Baulac; Federico Zara; Bobby P C Koeleman; Thomas Haaf; Eric LeGuern; Christel Depienne Journal: Nat Genet Date: 2014-04-20 Impact factor: 38.330
Authors: H L Wilson; A C C Wong; S R Shaw; W-Y Tse; G A Stapleton; M C Phelan; S Hu; J Marshall; H E McDermid Journal: J Med Genet Date: 2003-08 Impact factor: 6.318
Authors: Aleksandr Shcheglovitov; Olesya Shcheglovitova; Masayuki Yazawa; Thomas Portmann; Rui Shu; Vittorio Sebastiano; Anna Krawisz; Wendy Froehlich; Jonathan A Bernstein; Joachim F Hallmayer; Ricardo E Dolmetsch Journal: Nature Date: 2013-10-16 Impact factor: 49.962
Authors: João Peça; Cátia Feliciano; Jonathan T Ting; Wenting Wang; Michael F Wells; Talaignair N Venkatraman; Christopher D Lascola; Zhanyan Fu; Guoping Feng Journal: Nature Date: 2011-03-20 Impact factor: 49.962
Authors: Sergio Serrada-Tejeda; Rosa M Martínez-Piédrola; Nuria Máximo-Bocanegra; Patricia Sánchez-Herrera-Baeza; Marta Pérez-de-Heredia-Torres Journal: Front Neurosci Date: 2022-07-04 Impact factor: 5.152
Authors: Julián Nevado; Sixto García-Miñaúr; María Palomares-Bralo; Elena Vallespín; Encarna Guillén-Navarro; Jordi Rosell; Cristina Bel-Fenellós; María Ángeles Mori; Montserrat Milá; Miguel Del Campo; Pilar Barrúz; Fernando Santos-Simarro; Gabriela Obregón; Carmen Orellana; Harry Pachajoa; Jair Antonio Tenorio; Enrique Galán; Juan C Cigudosa; Angélica Moresco; César Saleme; Silvia Castillo; Elisabeth Gabau; Luis Pérez-Jurado; Ana Barcia; Maria Soledad Martín; Elena Mansilla; Isabel Vallcorba; Pedro García-Murillo; Franco Cammarata-Scalisi; Natálya Gonçalves Pereira; Raquel Blanco-Lago; Mercedes Serrano; Juan Dario Ortigoza-Escobar; Blanca Gener; Verónica Adriana Seidel; Pilar Tirado; Pablo Lapunzina Journal: Front Genet Date: 2022-04-12 Impact factor: 4.772
Authors: Sameer C Dhamne; Jill L Silverman; Alexander Rotenberg; Jacqueline N Crawley; Mustafa Sahin; Chloe E Super; Stephen H T Lammers; Mustafa Q Hameed; Meera E Modi; Nycole A Copping; Michael C Pride; Daniel G Smith Journal: Mol Autism Date: 2017-06-15 Impact factor: 7.509
Authors: Silvia De Rubeis; Paige M Siper; Allison Durkin; Jordana Weissman; François Muratet; Danielle Halpern; Maria Del Pilar Trelles; Yitzchak Frank; Reymundo Lozano; A Ting Wang; J Lloyd Holder; Catalina Betancur; Joseph D Buxbaum; Alexander Kolevzon Journal: Mol Autism Date: 2018-04-27 Impact factor: 7.509